To further enhance tumor killing efficacy and decrease the OTOT of CAIX targeted CAR-T cells, we have designed an anti-CAIX/CD70 dual-targeted CAR-T cell therapy that is activated in the presence of either CAIX or CD70, thus killing CAIX low expressing tumor cells and preventing potential antigen escape [59]. Here, CD70 is linked to neoplasm.